Data structures via C++: objects by evolution objects by evolution

By Berman, A. Michael.. New York : Oxford University Press, 1997 . 471 p. : , Includes index. 0195108434

Place Hold on Data structures via C++: objects by evolution

The production of space /

By Lefebvre, Henri.. Oxford : Basil Blackwell, 1991 . 454 p. : , Includes index. 24 cm.. 0631181776 (paperback) | 9780631181774 (paperback)

Place Hold on The production of space /

Vampire Mountain /

By Shan, Darren.. Boston : Little, Brown, 2002 . 199 p. ; , Sequel to: Tunnels of blood. 22 cm.. 0316608068

Place Hold on Vampire Mountain /

Barry's advanced construction of buildings /

By Emmitt, Stephen.. Chichester, U.K. ; | Ames, Iowa : Wiley-Blackwell, 2010 . ix, 582 p. : 25 cm.. 9781405188531 (pbk. : alk. paper) | 1405188537 (pbk. : alk. paper)

Place Hold on Barry's advanced construction of buildings /

Brain - Bolt (EEG Based Mind Aid) /

By Gulzar, Muhammad Tayyab . . 48 p.;

Place Hold on Brain - Bolt (EEG Based Mind Aid) /

CDCA-Bound Carbon-Based Nanoparticles for the Treatment of Cognitive Impairment and Neuropathy Associated with Diabetes Mellitus /

By Noreen, Samra . . 99p. , Diabetes Mellitus (DM) is a severe metabolic disorder defined by hyperglycemia, which leads to cognitive impairment and neuropathy. It is characterized by chronic pain, sensory loss, impaired motor coordination, and cognitive decline. According to the WHO (2024) and International Diabetes Federation (IDF) statistics, neuropathy affects over 50% of people with type 1 and type 2 diabetes. Current treatments for diabetic neuropathy provide only partial relief and fail to stop neurodegeneration, highlighting the need for novel strategies that both restore metabolic balance and protect neural function. Chenodeoxycholic acid (CDCA), a primary bile acid with antiinflammatory and neuroprotective effects, is limited by toxicity at high doses. CDs, owing to their ultra-small size, biocompatibility, and blood-brain barrier (BBB) permeability, are ideal for treating diabetic neuropathy and cognitive impairment. N-doped CDs were synthesized hydrothermally and conjugated with CDCA via carbodimide coupling. FTIR confirmed preserved functional groups, while UV-Vis showed π–π stacking and hydrogen bonding. Hemocompatibility testing revealed <5% hemolysis, confirming blood safety. Drug loading efficiency was ~ 99.6% (2489.82 bound from 2500 µg). Sustained release analysis showed ~ 17% release at 24 h and ~ 29% over 7 days without a burst effect. In-vivo, diabetic mice were grouped into control, free CDCA, CDCA-NCDs, and insulin glargine. The nanoconjugate was administered at a dose of 10 mg/kg on day 1 st, 7th and 14th compared to daily free CDCA. Behavioral tests (nociception, anxiety, and cognition) showed significant improvements (p < 0.05-0.0001) with CDCA-NCDs. Glycemic control, weight, and histopathology also favored CDCA-NCDs over free CDCA. Overall, CDCA-NCDs demonstrated excellent safety, efficient drug loading, controlled release, and superior therapeutic outcomes, supporting them as a promising low-frequency dosing strategy for neuroprotection and metabolic regulation in diabetic neuropathy. 30cm.